Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8038 clinical trials
Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers

This is a non-randomised study to develop personalised treatment approaches in participants with Locally Advanced Head and Neck Cancer (HNC) of the oropharynx and base of skull by integrating the use of MR-guided Adaptive Radiotherapy (MRgRT) and functional image-guided radiotherapy (FIgRT).

metastasis
cancer
platinum-based chemotherapy
neck cancer
squamous cell carcinoma of head and neck
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

The purpose of this study is to determine the safety, tolerability; Recommended Phase 2 Dose (RP2D), optimal ramp-up dosing schedule; and to evaluate preliminary activity of BGB-11417 monotherapy.

  • 0 views
  • 19 Feb, 2024
  • 2 locations
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies

This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.

  • 0 views
  • 19 Feb, 2024
  • 2 locations
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor

Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

metastasis
cancer
solid tumor
psychiatric disorder
advanced solid tumor
  • 0 views
  • 19 Feb, 2024
  • 1 location
S0820, Adenoma and Second Primary Prevention Trial (PACES)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing the event rate of adenomas and second primary colorectal cancers at three years in patients previously treated for stage 0 to III colon or rectal cancer.

  • 0 views
  • 02 Dec, 2024
  • 1 location
Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study

Peripheral blood mononuclear cell collection protocol for tumor immunotherapy study of UCAR-T cells

  • 0 views
  • 19 Feb, 2024
  • 1 location
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the second part will include 3 expansion cohorts of 15 patients: B1: anti-PD-1 refractory advanced NSCLC cohort …

ocular melanoma
cancer treatment
liver metastasis
cancer
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
  • 1 location
PTX-35 in Patients With Advanced Solid Tumors

A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care

metastasis
liver metastasis
unresectable solid tumor
solid tumour
gilbert's syndrome
  • 0 views
  • 19 Feb, 2024
  • 1 location
First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors

The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone or in combination with programmed cell death protein-1 (PD-1) inhibitors in treating solid cancers. ABBV-CLS-579 is an investigational drug being developed for the treatment of solid tumors. The study has two arms - …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

The 4SCAR-CD276-modified T cells (4SCAR-276) can recognize and kill tumor cells through the recognition of CD276, a surface protein expressed at high levels on many types of tumors but at low levels on normal tissues.

tyrosine
metastasis
monoclonal antibodies
recurrent solid tumor
serum bilirubin
  • 0 views
  • 19 Feb, 2024
  • 3 locations